Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study
暂无分享,去创建一个
Andrew Briggs | Mark Sculpher | Roberto Ferrari | Jane Wolstenholme | Michel Bertrand | A. Hall | M. Sculpher | J. Deckers | M. Simoons | A. Briggs | W. Remme | R. Ferrari | M. Bertrand | K. Fox | J. Wolstenholme | B. Mihaylova | Borislava Mihaylova | Jaap Deckers | Maarten Simoons | Alistair Hall | Willem J Remme | Kim Fox
[1] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[2] B. Pitt,et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.
[3] Dick M. Goedhart,et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. , 2006, European heart journal.
[4] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[5] M. Pfeffer,et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.
[6] J. Brazier,et al. Deriving a preference-based single index from the UK SF-36 Health Survey. , 1998, Journal of clinical epidemiology.
[7] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[8] J E Ware,et al. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. , 1998, Journal of clinical epidemiology.
[9] Ron Goeree,et al. Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[10] S. Yusuf,et al. Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003 .
[11] S. Yusuf,et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. , 2003, Circulation.
[12] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[13] M. Aoki,et al. Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model , 2001, Hypertension.
[14] H. Drexler,et al. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. , 1997, Circulation.
[15] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[16] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[17] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[18] Kukin Ml. The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.
[19] G. Lamas,et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.
[20] J Raftery,et al. NICE: faster access to modern treatments? Analysis of guidance on health technologies , 2001, BMJ : British Medical Journal.
[21] Disciplinary Committee,et al. Royal Pharmaceutical Society of Great Britain , 2002 .
[22] D. Vaughan,et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. , 1998, Hypertension.